source
- RNAi developers see surge in IPOs and funding as industry interest revivesBioPharma Dive’s latest data‑visualization series highlights a rapid rise in interest and investment for companies developing RNA interference (RNAi) medicines. After a years‑long lull, more than…
- US proposes new biotech investment limits on China, but licensing deals remain allowedThe U.S. Treasury announced a proposal to curb outbound investments in Chinese biotechnology, citing national‑security concerns. The plan would limit U.S. persons from funding certain bio‑derived c…